Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
11,265 total articles
Ovintiv (OVV) trades at ~5.3x EV/EBITDA with an enterprise value of roughly $22.8B and a market cap near $16.7B. Trailing free cash flow was negative, but adjusted forward cash generation and recent strategic assets sales/support for the balance sheet make a compelling risk-reward: entry at $59.59, stop $52.00, primary target $71.00 (mid-term, 45 t…
Bar Harbor Bankshares (BHB) offers a balanced risk-reward: modest valuation (P/B ~1.06, P/E ~13.9), a 3.7% yield, and consistent free cash flow. Technical weakness under short-term moving averages gives an actionable entry around $33.50 for a mid-term swing toward $38.00, with a conservative stop at $31.00.
Nebius Group is converting AI demand into outsized revenue growth and a widening moat in AI infrastructure. Strong Q1 results, major long-duration contracts and capacity commitments support a directional long trade with a $330 target over 180 trading days and a protective stop at $185.
Celestica plunged despite beating Q1 results and lifting guidance; fundamentals and a strategic AMD partnership argue for upside. This trade idea lays out an entry at $365, stop at $330 and a target at $435 with a mid-term horizon of 45 trading days.
nLIGHT is a smaller-cap laser specialist that has moved from cyclical optics supplier to a defense-focused beneficiary of directed-energy demand. With accelerating Aerospace & Defense revenue, improving margins, and visible program catalysts, the stock looks tradeable long from current levels. The trade below balances upside to analyst targets with…
Freightos (CRGO) is a small-cap SaaS play in digital freight booking. With a $106M market cap, recent mixed results, and heavy short-volume in May, the stock offers a conservative, asymmetric trade: buy into a transition year where revenue expectations are modest and upside comes from re-acceleration of bookings and margin leverage.
BlackLine is a cash-generative, entrenched finance automation platform that looks mispriced relative to its franchise and free cash flow. Recent AI M&A, engagement from an activist, and a large fund stake create near-term catalysts. Risk is real - leverage and a high headline multiple - but a tactical long with a clear stop and a $40 target fits th…
Core Scientific has shifted the narrative from low-margin self-mining to high-density colocation for AI and blockchain customers. With colocation revenue growing to $65M in 2025, a $500M expansion facility, bullish technicals and concentrated short interest, CORZ offers an asymmetric trade versus legacy peers. This idea lays out an actionable long …
Apple ($AAPL) is trading at fresh highs on persistent services revenue and massive free cash flow. The company’s core hardware franchises plus recurring services form the “three golden apples” that justify a measured long trade. Technicals are stretched, so enter at the current level with a firm stop and a 180 trading-day target that assumes modest…
Citigroup is not only integrating AI into its trading and services franchises but also beginning to show returns that justify a constructive trade. Valuation is reasonable at roughly $212B market cap, earnings per share of $7.63 and an annualized dividend that yields ~1.9%. This trade targets a recovery toward the recent 52-week high while sizing r…
Tarsus reported Q1 XDEMVY sales of $145M, up 85% year-over-year, and reaffirmed full-year guidance of $670-700M. The stock sold off after investors wanted a guidance raise. Fundamentals — rapid revenue growth, very high gross margins and narrowing losses — support a mid-term long trade from a dip toward $64 with a $78 target and a $59 stop.
Boston Scientific (BSX) has been punished hard: the stock trades near $53.40 after a steep move from a $109.50 52-week high. That drawdown has pushed valuation to reasonable levels (P/E ~22, EV/EBITDA ~15.8) while free cash flow remains healthy at roughly $3.48B. For traders willing to take a medium-term view, a disciplined long entry around $53.40…
Dollar General (DG) has pulled back into a valuation that looks compelling relative to its cash generation and dividend. The business still serves a defensive, value-conscious customer base and produces roughly $2.39B in free cash flow, but macro pressure on lower-income households and margin headwinds mean this is a trade, not a no-brainer buy-and…
Alphabet looks like a buy from current levels: robust free cash flow ($64.4B), low net leverage (debt/equity 0.16) and continued AI investments create upside. Near-term technicals are extended (RSI 71.6) and investor focus on Google I/O and potential bond issuance raises event risk. Trade plan: enter at $398.75, stop $375.00, target $460.00 over a …
Micron’s role as a primary supplier of high-bandwidth memory and multi-qualified partner for leading AI platforms has pushed its stock to the front of the market. Strong revenue prints, robust free cash flow, and constrained supply fundamentals create a tradeable AI premium. This idea lays out a mid-term long entry, targets, stop, catalysts and the…
Zscaler is trading below its recent highs after sector volatility, but fundamentals still point to durable demand for cloud-native zero trust security. The stock's technical setup and manageable short interest create a constructive risk/reward for a mid-term swing trade. Entry $155.00, target $190.00, stop $142.00; horizon: mid term (45 trading day…
Hims & Hers (HIMS) sold off after Q1 results that showed margin compression and a net loss, but revenue growth, raised 2026 guidance and a clear path to branded GLP-1 distribution make the pullback a buyable setup. Enter around $24.00 with a $19.50 stop and a $36.00 target over a 180 trading-day horizon.
Roche’s recent SERD program failure triggered a broad overreaction across endocrine-oncology names. Olema has been pulled down with the group, but the company’s program, clinical pathway and timeline differ enough that the market appears to be pricing in an unjustified binary failure. This trade targets a recovery-driven rebound over the next 45 tr…
Nvidia remains the de facto AI infrastructure provider. With earnings due 05/20/2026 and estimates calling for another blowout quarter, I am buying into NVDA today to capture pre-earnings momentum and the probable post-print re-rating. The trade is event-driven and high-risk, but technicals, fundamentals and cash flow support a constructive bias—wi…
Dollar General (DG) is trading at a meaningful discount from its 52-week high despite solid free cash flow, a mid-teens P/E and a dividend yield north of 2%. Weak guidance and macro pressure pushed shares into oversold territory; we see a mid-term recovery play with defined risk and a target near technical resistance around $120-$125.
POET has gone from near-collapse narratives to euphoric price action after a $50 million initial purchase order from Lumilens and new partnerships with LITEON and Lessengers. The stock is richly valued against minuscule revenue, but momentum and a clear commercial pathway to scaled orders create a tradeable asymmetric setup. This is a swing trade f…
Applied Optoelectronics is converting hyperscaler demand into real revenue with multiple large orders, a major capacity expansion and product roadmaps (800G to 1.6T) ready for volume. The economics are stretched today - valuation is elevated - but balance-sheet liquidity, low leverage and a string of multi-hundred-million-dollar orders argue that t…
Blue Owl (OWL) has been through a painful reset as the private credit complex re-priced over the last year. With shares trading near the low end of the 52-week range, a high quarterly distribution, and free cash flow north of $1.28B, the market appears to have priced in worst-case outcomes. This trade idea targets a recovery back toward mid-cycle m…
Danone stepping back removes takeover premium uncertainty but does not undermine Lifeway's underlying business: consistent sales growth, clean balance sheet, and attractive operating returns. This is a mid-term swing trade that favors buying a measured pullback with a clear stop and a realistic upside target tied to the company’s history and near-t…
Arcutis is transitioning from pure R&D to a commercial growth story. ZORYVE posted $105.4M in Q1 2026 revenue (65% YoY) and management reaffirmed 2026 guidance of $480-495M. With pediatric label expansion, new formulations and a broader sales effort, the business is starting to compound. The setup favors a long trade with defined risk controls whil…
